Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progressionA Bernard-Tessier, C Baldini, Patricia Martin, et al.
ESMO Open|April 30, 2021
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancerA Guyot D'Asnières De Salins, G Tachon, R Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyA R Hansen, C Massard, P A Ott, et al.
ESMO Open|March 7, 2022
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trialsE F Nassif, J-Y Blay, C Massard, et al.
Investigational New Drugs|October 1, 2013
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphomaA Hollebecque, E Deutsch, C Massard, et al.
ESMO Open|June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistanceY Loriot, A Marabelle, J P Guégan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2017
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumoursA Hollebecque, R Bahleda, L Faivre, et al.
Pageof 9